Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]

  • Awaiting development
  • GID-TA11724
  • Expected publication date: TBC

23993-Pembrolizumab-for-Breast-Cancer-V1.0-DEC2024-NON-CONF.pdf